Abstract

 CADTH recommends that Nucala should be reimbursed by public drug plans for the treatment of patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) if certain conditions are met.
 Nucala should only be covered to treat adult patients with severe CRSwNP who have polyps on both sides of the nose, have already had at least 1 surgery to treat their nasal polyps or cannot have this type of surgery, and still have symptoms despite corticosteroid treatment for at least 3 months. When Nucala is first prescribed, physicians must submit a baseline Sino-nasal Outcome Test-22 (SNOT-22) score or endoscopy nasal polyp score so that response to treatment can be measured.
 Nucala should only be reimbursed in patients whose nasal polyps are responding to treatment with Nucala and if it is prescribed by a physician with expertise in managing severe CRSwNP. The cost of Nucala must be lowered to be cost-effective and affordable.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
